Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Avastin increases tumor response rates in breast cancer patients before surgery

Avastin increases tumor response rates in breast cancer patients before surgery

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Possible new drug targets for treating diffuse large B-cell lymphoma

Possible new drug targets for treating diffuse large B-cell lymphoma

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

EC grants marketing authorization for BENLYSTA to treat SLE

EC grants marketing authorization for BENLYSTA to treat SLE

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Half-matched transplants widen donor pool for leukemia and lymphoma

Half-matched transplants widen donor pool for leukemia and lymphoma

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.